ArticleInternational journal of molecular sciences2026
Peripheral Mononuclear Cells Metabolomics in Obstructive Sleep Apnea Syndrome (OSAS): An Exploratory Pilot Study of Immunometabolic Signatures.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Obstructive Sleep Apnea Syndrome (OSAS) is associated with systemic inflammation and immune dysfunction, yet the specific metabolic alterations within immune cells remain poorly understood. In this exploratory study, we characterized the metabolome of peripheral mononuclear cells (PMNCs) from patients with OSAS and healthy controls to investigate potential immunometabolic signatures associated with the disease. Initial analyses identified 21 nominally differentially abundant metabolites between OSAS patients and controls, suggesting trends such as the depletion of carnitines and alterations in fatty acid and neurotransmitter metabolism. However, following correction for multiple testing (False Discovery Rate, FDR), only putatively annotated cis,cis-muconic acid remained statistically significant. Furthermore, pathway enrichment analysis highlighted exploratory trends primarily associated with SLC-mediated transmembrane transport and energy metabolism. Our findings indicate that while OSAS PMNCs exhibit metabolic shifts suggestive of cellular stress, most of these alterations represent nominal trends that require validation in larger cohorts. The robust identification of putatively annotated cis,cis-muconic acid highlights a potential target of interest. In this exploratory pilot study, given the absence of polysomnographic and objective hypoxia parameters in most participants, observed metabolic alterations are described as associated with, rather than directly caused by, intermittent hypoxia. Overall, this study provides a hypothesis-generating framework for future research on the immunometabolic consequences of OSAS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.